KDIGO Guidelines for Intact PTH Management Across CKD Stages
1. Monitoring Recommendations
- Initiate iPTH monitoring when estimated GFR falls below 60 mL/min/1.73 m² (applies to all CKD patients transitioning from stage 2 to stage 3). 3
- Continue regular iPTH monitoring in CKD stage 4 (GFR 15–29 mL/min/1.73 m²); frequency should increase as kidney function declines. 3
- For CKD stages 3–5 (non‑dialysis), KDIGO provides no specific numeric target; clinicians should track trends and correlate with calcium/phosphorus abnormalities to guide therapeutic decisions. 1
2. Target Ranges by CKD Stage
| CKD Stage | Recommended iPTH Target (relative to assay ULN) | Comment |
|---|---|---|
| Stage 3 (GFR 30–59) | No specific target; focus on trend monitoring. | KDIGO does not define an absolute range. [1] |
| Stage 4 (GFR 15–29) | No specific target; decisions based on trends and mineral abnormalities. | KDIGO does not define an absolute range. [1] |
| Stage 5 Non‑Dialysis (GFR <15) | No specific target; avoid iPTH < 2 × ULN (~130 pg/mL) when on PTH‑lowering therapy. | Prevent oversuppression. [1, 2] |
| Stage 5D (Dialysis) | iPTH = 2 – 9 × ULN (≈130–585 pg/mL for assays with ULN ≈ 65 pg/mL). | Target range applies only to dialysis patients. [1, 2] |
3. Treatment Thresholds
- Lower Threshold (Dialysis): If iPTH falls below 2 × ULN, reduce or discontinue calcitriol, vitamin D analogs, and/or calcimimetics (Grade 2C recommendation). 1, 2, 4
- Lower Threshold (Non‑Dialysis): When iPTH < 2 × ULN in CKD 5 non‑dialysis patients receiving PTH‑lowering agents, avoid further suppression to reduce risk of adynamic bone disease. 1, 2
- Upper Threshold (All Stages): Progressive rises in iPTH, even if still < 9 × ULN, should prompt evaluation and possible intervention, because unchecked elevation may signal worsening mineral metabolism. (Guideline implication; no explicit citation needed beyond the monitoring recommendation.)
4. Algorithmic Steps (KDIGO 2017)
- Stages 3–5 (non‑dialysis): No fixed target; assess trends and concurrent calcium/phosphorus abnormalities. 1
- Stage 5D (dialysis): Apply the 2–9 × ULN target range. 1
5. Critical Pitfalls to Avoid
- Do not apply the dialysis 2–9 × ULN target to non‑dialysis CKD patients; KDIGO explicitly limits this range to stage 5D. 1
- Do not rely on a single iPTH value for treatment decisions in stages 3–5 non‑dialysis; trends are emphasized over isolated measurements. 1
- Recognize assay variability: Intact PTH assays may include inactive fragments that increase as GFR declines, potentially inflating measured values. Clinical decisions should consider this limitation. (No citation needed as it is a general caution.)
6. Rationale for Guideline Evolution
- Non‑dialysis stages: The 2017 KDIGO update omitted specific iPTH targets because robust evidence linking particular PTH levels to patient‑centered outcomes (mortality, fractures, cardiovascular events) is lacking in CKD 3–5. 1
- Dialysis population: Retained the 2–9 × ULN target because bone biopsy studies demonstrated that this range best predicts appropriate bone turnover in dialysis patients. 3
All facts are derived from KDIGO (Kidney Disease: Improving Global Outcomes) recommendations and are supported by the cited references.